Indications and clinical use:1

Prolia (denosumab injection) is indicated:

for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral and hip fractures.

as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

as a treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT), who are at high risk for fracture.

as a treatment to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy, who have low bone mass and are at high risk for fracture.

as a treatment to increase bone mass in women and men at high risk for fracture due to sustained systemic glucocorticoid therapy.

as a treatment to increase bone mass in women and men at high risk for fracture who are starting or have recently started long-term glucocorticoid therapy.

Prolia is not indicated for use in pediatric patients.

Contraindications

Hypersensitivity to the drug or any ingredient in the formulation, including any non-medicinal ingredient or component of the container. Anaphylactic reactions have been reported.

Hypocalcemia

Patients who are pregnant or trying to become pregnant. Verify the pregnancy status of women of reproductive potential prior to initiating Prolia. Advise them that Prolia may cause fetal harm when administered to a pregnant woman and to use effective contraception during therapy and for at least 5 months after the last dose of Prolia.

Relevant Warnings and Precautions

Contains same active ingredient as XGEVA®; do not use concurrently

Adequate intake of calcium and vitamin D is important in all patients

Hypercalcemia has been reported in clinical trials in pediatric patients with osteogenesis imperfecta treated with denosumab. Some cases required hospitalization and were complicated by acute renal injury.

Hypocalcemia, including severe cases; clinical monitoring of calcium levels is recommended; follow standard medical care guidelines for signs and symptoms

In severe renal impairment or dialysis, there is a greater risk of hypocalcemia; adequate intake of calcium and vitamin D is important

Serious infections

Epidermal and dermal adverse events

Osteonecrosis of the jaw (ONJ); risk may increase with duration of exposure to Prolia; evaluate for ONJ risk factors before starting treatment; dental examination is recommended for those with risk factors; good oral hygiene practices should be maintained during treatment and invasive dental procedures should be avoided

Atypical femoral fractures

Multiple vertebral fractures following discontinuation of Prolia treatment

Significant suppression of bone remodelling

Potential for greater sensitivity in older patients

Not recommended in nursing women

Potential for female partner and fetal exposure unlikely when taken by men

Latex sensitivity

Hypersensitivity vasculitis

Drug reaction with eosinophilia and systemic symptoms (DRESS)

Musculoskeletal pain, including severe cases

For more information:

Please consult the Product Monograph at www.amgen.ca/Prolia_PM.pdf for important information relating to adverse reactions, drug interactions and dosing.

The Product Monograph is also available by calling us at 1-866-502-6436.

Additional Resources
FREEDOM Clinical Trial Icon
FREEDOM Clinical Trial

Access the FREEDOM trial in the virtual library.

Virtual LibraryArrow Image
References

You are now leaving the Prolia.ca website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave Prolia.ca?

You are now leaving the Prolia.ca website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

Proceed